期刊
CANCER SCIENCE
卷 104, 期 1, 页码 124-129出版社
WILEY-BLACKWELL
DOI: 10.1111/cas.12046
关键词
-
类别
资金
- Ministry of Education, Culture, Sports, Science and Technology of Japan [16209013, 17016061, 15659097]
- Japan Science and Technology Agency
- Ministry of Health, Labor and Welfare of Japan [15-17, 19-14]
- Akiyama Life Science Foundation
- Ono Foundation
- Grants-in-Aid for Scientific Research [15659097, 16209013, 24590448, 23590427, 17016061, 24659592, 24659165] Funding Source: KAKEN
Survivin, a member of the inhibitor of apoptosis protein (IAP) family containing a single baculovirus IAP repeat domain, is highly expressed in cancerous tissues but not in normal counterparts. Our group identified an HLA-A24-restricted antigenic peptide, survivin-2B8088 (AYACNTSTL), that is recognized by CD8 + CTLs and functions as an immunogenic molecule in patients with cancers of various histological origins such as colon, breast, lung, oral, and urogenital malignancies. Subsequent clinical trials with this epitope peptide alone resulted in clinical and immunological responses. However, these were not strong enough for routine clinical use as a therapeutic cancer vaccine, and our previous study of colon cancer patients indicated that treatment with a vaccination protocol of survivin-2B8088 plus incomplete Freund's adjuvant (IFA) and alpha-interferon (IFN alpha) conferred overt clinical improvement and enhanced the immunological responses of patients. In the current study, we further investigated whether this vaccination protocol could efficiently provide not only improved immune responses but also better clinical outcomes for advanced pancreatic cancers. Tetramer and enzyme-linked immunosorbent spot analysis data indicated that more than 50% of the patients had positive clinical and immunological responses. In contrast, assessment of treatment with IFN alpha only to another group of cancer patients resulted in no obvious increase in the frequency of survivin-2B80-88 peptide-specific CTLs. Taken together, our data clearly indicate that a vaccination protocol of survivin-2B80-88 plus IFA and IFN alpha is very effective and useful in immunotherapy for this type of poor-prognosis neoplasm. This trial was registered with the UMIN Clinical Trials Registry, no. UMIN000000905. (Cancer Sci 2013; 104: 124129)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据